Stoke Therapeutics’ (STOK) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $22.00 price objective on the stock.

Several other research firms also recently commented on STOK. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital restated a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. Finally, HC Wainwright boosted their price target on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Trading Up 0.8 %

Stoke Therapeutics stock opened at $8.33 on Tuesday. The business’s fifty day simple moving average is $9.49 and its two-hundred day simple moving average is $11.49. Stoke Therapeutics has a 12 month low of $5.80 and a 12 month high of $17.58. The company has a market capitalization of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. On average, equities research analysts predict that Stoke Therapeutics will post -2.01 EPS for the current year.

Insiders Place Their Bets

In other news, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,532 shares of company stock worth $143,332 over the last quarter. 11.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP boosted its stake in Stoke Therapeutics by 10.1% during the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after buying an additional 471,240 shares during the last quarter. Baker BROS. Advisors LP boosted its stake in Stoke Therapeutics by 6.1% during the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock valued at $51,111,000 after buying an additional 265,395 shares during the last quarter. Toronto Dominion Bank bought a new position in Stoke Therapeutics during the fourth quarter valued at approximately $35,001,000. State Street Corp boosted its stake in Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after buying an additional 137,145 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in Stoke Therapeutics by 2.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after purchasing an additional 38,446 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.